Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alcon’s Cipro HC Otic Product Website Draws FDA Warning Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA objects to website claims that Cipro HC Otic is superior to Cortisporin. Alcon’s site also fails to reveal important risk information about the ear drops product, the agency’s ad review division says.

You may also be interested in...

Alcon Gets Third FDA Warning On Sales Claims For Eye And Ear Drugs

Nevanac joins Cipro HC Otic and Travaton in being cited by the agency’s advertising division.

India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs

Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts